Addition of baricitinib to mainstay of treatment improves signs and symptoms of atopic dermatitis, study finds
Adding the oral selective Janus kinase 1 and 2 inhibitor, baricitinib, to topical corticosteroid treatment significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis, a phase III study in JAMA Dermatology has suggested.…
Published: 15 October 2020
